Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CYDY NASDAQ:EWTX NASDAQ:TLRY NASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYDYCytoDyn$0.30-4.5%$0.29$0.10▼$0.49$394.49M1.231.64 million shs1.71 million shsEWTXEdgewise Therapeutics$14.35-2.0%$13.78$10.60▼$38.12$1.54B0.26731,608 shs670,556 shsTLRYTilray Brands$1.38-6.1%$0.76$0.35▼$1.88$1.62B1.8591.09 million shs50.56 million shsTVTXTravere Therapeutics$17.50-1.1%$16.36$8.98▼$25.29$1.58B0.741.69 million shs1.96 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYDYCytoDyn-3.26%+0.98%+5.01%-11.82%+124.52%EWTXEdgewise Therapeutics-2.05%-3.37%+0.84%+1.06%-23.87%TLRYTilray Brands-6.12%+20.00%+125.34%+214.92%-18.82%TVTXTravere Therapeutics-1.13%-2.34%+13.05%+16.82%+93.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYDYCytoDyn0.2007 of 5 stars0.02.00.00.00.60.01.3EWTXEdgewise Therapeutics2.2716 of 5 stars3.52.00.00.02.62.50.0TLRYTilray Brands2.1825 of 5 stars3.21.00.00.02.61.71.3TVTXTravere Therapeutics2.2906 of 5 stars3.43.00.00.02.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYDYCytoDyn 0.00N/AN/AN/AEWTXEdgewise Therapeutics 2.91Moderate Buy$40.55182.55% UpsideTLRYTilray Brands 2.33Hold$1.9440.40% UpsideTVTXTravere Therapeutics 2.87Moderate Buy$33.4391.02% UpsideCurrent Analyst Ratings BreakdownLatest CYDY, TVTX, TLRY, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $47.008/25/2025TLRYTilray BrandsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.50 ➝ $2.008/19/2025EWTXEdgewise TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $30.008/10/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/8/2025EWTXEdgewise TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$48.00 ➝ $49.008/7/2025TVTXTravere TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform8/7/2025TVTXTravere TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $31.008/7/2025TVTXTravere TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $32.007/30/2025EWTXEdgewise TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$46.007/29/2025TLRYTilray BrandsZelman & AssociatesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral7/1/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$30.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYDYCytoDynN/AN/A$0.00 per share94.21($0.08) per shareN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/A$5.59 per shareN/ATLRYTilray Brands$821.31M1.85$0.14 per share10.17$1.40 per share0.99TVTXTravere Therapeutics$233.18M6.69N/AN/A$0.37 per share47.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYDYCytoDyn$3.74M$0.0130.02∞N/AN/AN/A-4.40%9/2/2025 (Estimated)EWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.65%-29.18%11/6/2025 (Estimated)TLRYTilray Brands-$2.19B-$2.31N/AN/AN/A-265.69%-6.83%-5.45%10/9/2025 (Estimated)TVTXTravere Therapeutics-$321.55M-$2.04N/AN/AN/A-50.64%-717.68%-30.69%10/30/2025 (Estimated)Latest CYDY, TVTX, TLRY, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025EWTXEdgewise Therapeutics-$0.42-$0.34+$0.08-$0.34N/AN/A8/6/2025Q2 2025TVTXTravere Therapeutics-$0.28-$0.14+$0.14-$0.14$100.18 million$94.84 million7/28/2025Q4 2025TLRYTilray Brands-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 million7/25/2025Q4 2025CYDYCytoDynN/A-$0.01N/A-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYDYCytoDynN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYDYCytoDynN/A0.250.25EWTXEdgewise TherapeuticsN/A28.8728.87TLRYTilray Brands0.202.461.49TVTXTravere Therapeutics9.502.001.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYDYCytoDyn5.06%EWTXEdgewise TherapeuticsN/ATLRYTilray Brands9.35%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCYDYCytoDyn0.54%EWTXEdgewise Therapeutics23.20%TLRYTilray Brands0.60%TVTXTravere Therapeutics4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYDYCytoDyn201.26 billion1.25 billionNot OptionableEWTXEdgewise Therapeutics60105.35 million80.91 millionOptionableTLRYTilray Brands2,8421.10 billion1.09 billionOptionableTVTXTravere Therapeutics46089.14 million85.40 millionOptionableCYDY, TVTX, TLRY, and EWTX HeadlinesRecent News About These CompaniesWalleye Capital LLC Sells 158,092 Shares of Travere Therapeutics, Inc. $TVTXAugust 29 at 5:20 AM | marketbeat.comTravere Therapeutics stock jumps after FDA approves reduced monitoring for FILSPARIAugust 28 at 1:25 PM | au.investing.comTravere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA NephropathyAugust 27 at 5:09 PM | businesswire.comInvesco Ltd. Lowers Position in Travere Therapeutics, Inc. $TVTXAugust 27 at 3:30 AM | marketbeat.com21,094 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Penn Capital Management Company LLCAugust 26, 2025 | marketbeat.comWall Street Zen Downgrades Travere Therapeutics (NASDAQ:TVTX) to HoldAugust 26, 2025 | marketbeat.comTravere Therapeutics, Inc. $TVTX Shares Purchased by Charles Schwab Investment Management Inc.August 26, 2025 | marketbeat.comCanaccord Genuity Sticks to Its Buy Rating for Travere Therapeutics (TVTX)August 25, 2025 | theglobeandmail.comVanguard Group Inc. Reduces Stock Position in Travere Therapeutics, Inc. $TVTXAugust 25, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Cut to "Hold" at Wall Street ZenAugust 25, 2025 | americanbankingnews.comCandriam S.C.A. Takes Position in Travere Therapeutics, Inc. $TVTXAugust 24, 2025 | marketbeat.comTravere Therapeutics Earnings Call Highlights FILSPARI SuccessAugust 23, 2025 | theglobeandmail.comAberdeen Group plc Raises Stock Holdings in Travere Therapeutics, Inc. $TVTXAugust 22, 2025 | marketbeat.comNuveen LLC Makes New Investment in Travere Therapeutics, Inc. $TVTXAugust 20, 2025 | marketbeat.comWall Street Zen Upgrades Travere Therapeutics (NASDAQ:TVTX) to "Buy"August 19, 2025 | americanbankingnews.comCiti Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA CatalystsAugust 18, 2025 | msn.comWall Street Zen Upgrades Travere Therapeutics (NASDAQ:TVTX) to BuyAugust 17, 2025 | marketbeat.comInformed Momentum Co LLC Invests $2.69 Million in Travere Therapeutics, Inc. (NASDAQ:TVTX)August 14, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Boosts Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)August 13, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by AnalystsAugust 12, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Outlook for TVTX EarningsAugust 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025Tilray's High Hopes: The Catalyst Driving Cannabis StocksBy Jeffrey Neal Johnson | August 21, 2025CYDY, TVTX, TLRY, and EWTX Company DescriptionsCytoDyn OTCMKTS:CYDY$0.30 -0.01 (-4.46%) As of 08/29/2025 03:58 PM EasternCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Edgewise Therapeutics NASDAQ:EWTX$14.35 -0.30 (-2.05%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$14.36 +0.01 (+0.07%) As of 08/29/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Tilray Brands NASDAQ:TLRY$1.38 -0.09 (-6.12%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.38 0.00 (-0.36%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.Travere Therapeutics NASDAQ:TVTX$17.50 -0.20 (-1.13%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$17.52 +0.02 (+0.11%) As of 08/29/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
